Oncoinvent, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, today announced the successful enrollment of the sixth patient into the safety lead-in ...

Oncoinvent has dosed the first subject in the Phase II clinical trial of Radspherin, an alpha-radiation therapy, for the ...